Comparison · NCT00675584-sae
Daily Budesonide vs Intermittent Budesonide: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Daily Budesonide vs Intermittent Budesonide: serious adverse events. Trial comparisons, record NCT00675584-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00675584-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0504 | 0.0246 | 0.1 | wilson | |
| Risk in group 2 | 0.0719 | 0.0395 | 0.127 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0216 | -0.0827 | 0.0379 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.7 | 0.274 | 1.79 | log | |
| Odds ratio, group 1 over group 2 | 0.684 | 0.253 | 1.85 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Daily Budesonide than on Intermittent Budesonide | 46.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Daily Budesonide | Participants will receive 0.5 mg of ICS (budesonide as Pulmicort Respules®) once a day at night, except during respiratory tract illnesses. During respiratory tract illnesses, participants will receive placebo each morning and 0.5 mg of budesonide each night for 7 days. | 7 | 139 | EG000 |
| Group 2 | Intermittent Budesonide | Participants will receive 1 mg of ICS (budesonide as Pulmicort Respules®) twice a day for 7 days at the onset of a respiratory tract illness; they will receive placebo ICS once a day at all other times during the study. | 10 | 139 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 1 year
Source ClinicalTrials.gov
Trial
- Title
- CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)
- NCT number
- NCT00675584
- Phases
- PHASE3
- Conditions
- Asthma
- Interventions
- Budesonide, Placebo Budesonide
- Lead sponsor
- Milton S. Hershey Medical Center
- Results first posted
- 2012-06-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00675584?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00675584-sae